secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001437749-23-017922
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica raises $37.5M in private placement; FDA lifts clinical hold on ReMEDy2 stroke trial
--------------------------------------------------------------------------------

- Raised $37.5M gross via 11,011,406 common shares at $3.40 each; management paid $3.91/share.
- FDA lifted clinical hold on Phase 2/3 ReMEDy2 trial for DM199 in acute ischemic stroke.
- Net proceeds to fund DM199 development and ReMEDy2 trial through interim analysis.
- Private placement expected to close June 23, 2023; resale registration to be filed.
- Related parties (board/management) invested $751,900; Craig-Hallum acted as placement agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923017922/0001437749-23-017922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923017922/dmtp20230620d_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-017922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer